Latest news

Cogent challenges Blueprint Medicines’ Ayvakit with strong trial data for rare immune disease

Cogent challenges Blueprint Medicines’ Ayvakit with strong trial data for rare immune disease

Joachim Eeckhout
Early trial data backs AstraZeneca's $1B bet on EsoBiotec’s CAR-T therapy

Early trial data backs AstraZeneca's $1B bet on EsoBiotec’s CAR-T therapy

Joachim Eeckhout
Boston biotech industry is under pressure due to a funding drought and Trump's policy

Boston biotech industry is under pressure due to a funding drought and Trump's policy

Joachim Eeckhout
MaaT Pharma partners with Clinigen to launch Europe’s first microbiome therapy for aGvHD

MaaT Pharma partners with Clinigen to launch Europe’s first microbiome therapy for aGvHD

Joachim Eeckhout
Vyne's BET inhibitor ends psoriasis trial after FDA hold

Vyne's BET inhibitor ends psoriasis trial after FDA hold

Joachim Eeckhout
Biokin scores phase 3 win for BMS backed bispecific ADC

Biokin scores phase 3 win for BMS backed bispecific ADC

Joachim Eeckhout
BerGenBio pivots and merges with radiopharma firm Oncoinvent after drug failure

BerGenBio pivots and merges with radiopharma firm Oncoinvent after drug failure

Joachim Eeckhout
Argenx inks $1.5B deal with Unnatural Products for oral peptide drugs

Argenx inks $1.5B deal with Unnatural Products for oral peptide drugs

Joachim Eeckhout
Amgen’s FGFR2b drug shows survival boost in phase 3 gastric cancer trial

Amgen’s FGFR2b drug shows survival boost in phase 3 gastric cancer trial

Joachim Eeckhout
AbbVie bets big on next-gen CAR-T with $2.1B Capstan buyout

AbbVie bets big on next-gen CAR-T with $2.1B Capstan buyout

Joachim Eeckhout
FDA eases restrictions on CAR-T cancer therapies

FDA eases restrictions on CAR-T cancer therapies

Joachim Eeckhout
Alphabet’s Calico inks $596M deal for anti-aging antibody

Alphabet’s Calico inks $596M deal for anti-aging antibody

Joachim Eeckhout
FirstBack
12
Next Last